Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 45 min ago
Peer-reviewedCC BY-NC-NDMolecular Therapy

Harnessing B19-directed CAR T cells for AAV vector administration in seropositive patients: The importance of the niche

  • Hanadi Saliba
  • David Alexandre Gross
  • Giuseppe Ronzitti
Open at sourcePDFDOICite

Abstract

Adeno-associated virus (AAV) vectors have significantly advanced in vivo gene therapy for monogenic diseases. Humoral immunity to AAVs represents a major challenge toward the application of this gene transfer modality in the larger population. Pre-existing neutralizing antibodies (Nabs) to AAV capsids reduce the number of patients eligible for treatment, while post-treatment humoral immunity prevents vector re-administration. Addressing this challenge remains a critical need in the field. In this issue of Molecular Therapy, Doshi et al.

Related

  1. Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain
    María Lloret Avellá, Mafalda Carmo, Núria Paladio Duran +1
    PLOS OnePeer-reviewedCC BY 4.0Full textSystems & synthetic biologyPharmacology & toxicologyPLOS
  2. Dynamic Changes in Small-Intestinal Bacterial Overgrowth Following Stricture-Directed Interventions in Patients With Crohn’s Disease: A Prospective Cohort Study
    Takanori Igarashi, Kentaro Tominaga, Kunihiko Yokoyama +9
    Journal of Neurogastroenterology and MotilityPeer-reviewedCC BY-NC 4.0Full textGenetics & genomicsPMC
  3. IgM-and IgG-cleaving enzyme facilitates AAV gene transfer in AAV-seropositive macaques
    Helen L. Wu, Zachary C. Elmore, Mark A. Ochoa +16
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textGenetics & genomicsCrossrefEurope PMCPMC
  4. Encephalitic alphavirus infection induces long-term humoral and cell-mediated responses in seropositive participants from Panama
    Courtney A. Cohen, Jean Paul Carrera, Josefrancisco Galué +18
    PLOS Neglected Tropical DiseasesPeer-reviewedCC BY 4.0Full textImmunologyPLOS
  5. Harnessing Particle Ions for FLASH Radiotherapy
    Alex J. Bembridge, Jonathan R. Hughes, Jason L. Parsons
    CellsPeer-reviewedCC BYFull textCell biologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{saliba2026harnessing,
  title = {{Harnessing B19-directed CAR T cells for AAV vector administration in seropositive patients: The importance of the niche}},
  author = {Hanadi Saliba and David Alexandre Gross and Giuseppe Ronzitti},
  journal = {Molecular Therapy},
  year = {2026},
  month = sep,
  doi = {10.1016/j.ymthe.2025.06.007},
  url = {https://hal.science/hal-05769992v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Harnessing B19-directed CAR T cells for AAV vector administration in seropositive patients: The importance of the niche
AU  - Hanadi Saliba
AU  - David Alexandre Gross
AU  - Giuseppe Ronzitti
PY  - 2026
DA  - 2026/09/29
JO  - Molecular Therapy
DO  - 10.1016/j.ymthe.2025.06.007
UR  - https://hal.science/hal-05769992v1
AB  - Adeno-associated virus (AAV) vectors have significantly advanced in vivo gene therapy for monogenic diseases. Humoral immunity to AAVs represents a major challenge toward the application of this gene transfer modality in the larger population. Pre-existing neutralizing antibodies (Nabs) to AAV capsids reduce the number of patients eligible for treatment, while post-treatment humoral immunity prevents vector re-administration. Addressing this challenge remains a critical need in the field. In this issue of Molecular Therapy, Doshi et al.
SN  - 1525-0016
SN  - 1525-0024
ER  -